Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4793633 | 0.93 | EPHX1 (0.45) | EPHX1SMN1; SMN2LMNANPSR1GAA | |
| SCHEMBL14540867 | 0.92 | EPHX1 (0.46) | EPHX1SMN1; SMN2LMNANPSR1GAA | |
| SCHEMBL4794135 | 0.92 | EPHX1 (0.46) | EPHX1SMN1; SMN2LMNANPSR1GAA | |
| SCHEMBL5437855 | 0.88 | EPHX1 (0.52) | EPHX1SMN1; SMN2LMNANPSR1HSD11B1 | |
| SCHEMBL4770967 | 0.86 | EPHX1 (0.47) | EPHX1SMN1; SMN2LMNANPSR1GAA | |
| SCHEMBL4767897 | 0.85 | EPHX1 (0.49) | EPHX1SMN1; SMN2LMNANPSR1GAA | |
| SCHEMBL4767981 | 0.85 | EPHX1 (0.43) | EPHX1SMN1; SMN2LMNANPSR1GAA | |
| SCHEMBL5441881 | 0.84 | EPHX1 (0.56) | EPHX1SMN1; SMN2LMNANPSR1HSD11B1 | |
| SCHEMBL4767944 | 0.84 | EPHX1 (0.56) | EPHX1SMN1; SMN2LMNANPSR1HSD11B1 | |
| SCHEMBL14540604 | 0.84 | EPHX1 (0.42) | EPHX1SMN1; SMN2LMNANPSR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066584-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-03-22 | — | — | US | claimed |
| WO-2007038138-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070066584-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066584-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066584-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066584-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | EPHX1 378/4885SMN1; SMN2 3627/4885LMNA 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.